PET imaging test for brain diseases using ¹⁸F-FCOB04
Part of Brain & nervous system clinical trials.
This trial tests a new PET imaging agent that targets a brain enzyme called MAO-B. It is designed to help doctors see changes in the brain linked to conditions like Alzheimer's, Parkinson's, and related disorders. Participating may improve understanding of your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75.
- Diagnosed with a neurodegenerative disease like Alzheimer's, Parkinson's, or related syndromes.
- Not currently taking or have stopped MAO-B inhibitor drugs (such as selegiline or rasagiline) for at least 14 days before the scan.
- No other severe medical conditions, history of brain surgery, tumor, or cyst that could affect the scan.
- No claustrophobia, substance abuse, or pregnancy/breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of brain scan (PET/CT) to look at a protein called MAO-B in people with Parkinson's disease or related conditions. The scan may help doctors understand more about the disease and could be part of your regular care.
This trial uses a special PET scan to see how a new imaging agent (called 11C-M503) travels through the body and brain. It may help researchers better understand brain conditions like Parkinson's disease.
This trial uses a new imaging agent (like a dye) to see signs of Parkinson's disease in the brain. If you have Parkinson's or a related condition like Lewy body dementia or multiple system atrophy, this scan may help researchers better understand these illnesses.
This study uses a new PET scan tracer called [11C]SY08 to take pictures of the brain in people with Parkinson's, multiple system atrophy, or dementia with Lewy bodies. It aims to see if this tracer can help better understand and tell apart these conditions.
This study tests if a new radioactive tracer called [18F]-MFBG can help doctors better distinguish between Parkinson's disease, multiple system atrophy (MSA), dementia with Lewy bodies, and Alzheimer's disease. It compares the new scan with two standard scans to see which is most accurate.
This study uses a special PET scan to look at MAO-A, a brain chemical linked to depression. It may help doctors better understand and diagnose depression.
Hear when a new Neurodegenerative Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.